Therefore, following the approval of Exenatide, development of GLP-1 drugs mainly focused on two directions: developing long-acting GLP-1RAs and oral GLP-1RAs (Figure 3)
With the popularity of GLP-1 agonists ever-increasing and over 150 GLP-1 drug candidates in development [3], the field is continually expanding, most recently into oncology and obesity-related cancers.[4] While most approved GLP-1RAs require subcutaneous injection, substantial work is being undertaken to move toward oral GLP-1 therapies [5], such as Rybelsus which was the first oral GLP-1RA approved by the FDA in 2019
People aged 60+ with a change in bowel habit lasting more than 6 weeks should also consult their GP
In summary, L-carnitine is an essential compound synthesized by the body and obtained through diet, vital for transporting fats into mitochondria to produce energy
With the increasing prevalence of metabolic diseases globally, interventions targeting GLP-1R could play an important role in reducing the burden of these conditions
Fenech AG, Ellul-Micallef R: Selenium glutathione peroxidase and superoxide dismutase in maltese asthmatic patients: effect of glucocorticoid administration